Page 265 - Read Online

Page 8 of 10 Gacad et al. Vessel Plus 2019;3:28 I http://dx.doi.org/10.20517/2574-1209.2019.011

II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007;115:1082-9.
12. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, et al. Percutaneous coronary intervention versus coronary-artery
bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72.
13. Hou L, Ghosh B, Hakeem A. A physiological approach to refine appropriateness of revascularization, clinical decision making and
prognosis in patients with multi vessel coronary artery disease. J Thorac Dis 2018;10:5661-5.
14. Mehta RH, Honeycutt E, Shaw LK, Milano CA, Smith PK, et al. Clinical and angiographic correlates of short- and long-term mortality
in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:1538-42.
15. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, et al. Long-term patency of saphenous vein and left internal mammary artery grafts
after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004;44:2149-56.
16. Meng M, Gao B, Wang X, Bai ZG, Sa RN, et al. Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent
in patients undergoing percutaneous coronary interventions: a meta-analysis. BMC Cardiovasc Disord 2016;16:34.
17. Mehta RH, Honeycutt E, Peterson ED, Granger CB, Halabi AR, et al. Impact of internal mammary artery conduit on long-term
outcomes after percutaneous intervention of saphenous vein graft. Circulation 2006;114:I396-401.
18. Saha T, Naqvi SY, Goldberg S. Hybrid revascularization: a review. Cardiology 2018;140:35-44.
19. Gąsior M, Zembala MO, Tajstra M, Filipiak K, Gierlotka M, et al. Hybrid revascularization for multivessel coronary artery disease.
JACC Cardiovasc Interv 2014;7:1277-83.
20. Harskamp RE, Brennan JM, Xian Y, Halkos ME, Puskas JD, et al. Practice patterns and clinical outcomes after hybrid coronary
revascularization in the United States: an analysis from the society of thoracic surgeons adult cardiac database. Circulation
2014;130:872-9.
21. Squiers JJ, Mack MJ. Coronary artery bypass grafting-fifty years of quality initiatives since Favaloro. Ann Cardiothorac Surg
2018;7:516-20.
22. Head SJ, Milojevic M, Taggart DP, Puskas JD. Current practice of state-of-the-art surgical coronary revascularization. Circulation
2017;136:1331-45.
23. Gaudino M, Mack MJ, Taggart DP. Additional arterial conduits in coronary artery bypass surgery: finally coming of age. J Thorac
Cardiovasc Surg 2018;156:541-3.
24. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation
1998;97:916-31.
25. Hess CN, Lopes RD, Gibson CM, Hager R, Wojdyla DM, et al. Saphenous vein graft failure after coronary artery bypass surgery:
insights from PREVENT IV. Circulation 2014;130:1445-51.
26. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, et al. Efficacy and safety of edifoligide, an E2F transcription
factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled
trial. JAMA 2005;294:2446-54.
27. Alexander JH, Smith PK. Coronary-artery bypass grafting. N Engl J Med 2016;374:1954-64.
28. Hindnavis V, Cho SH, Goldberg S. Saphenous vein graft intervention: a review. J Invasive Cardiol 2012;24:64-71.
29. Yahagi K, Kolodgie FD, Otsuka F, Finn AV, Davis HR, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.
Nat Rev Cardiol 2016;13:79-98.
30. Sarjeant JM, Rabinovitch M. Understanding and treating vein graft atherosclerosis. Cardiovasc Pathol 2002;11:263-71.
31. Lee M, Kong J. Current state of the art in approaches to saphenous vein graft interventions. Interv Cardiol 2017;12:85-91.
32. Davlouros P, Damelou A, Karantalis V, Xanthopoulou I, Mavronasiou E, et al. Evaluation of culprit saphenous vein graft lesions with
optical coherence tomography in patients with acute coronary syndromes. JACC Cardiovasc Interv 2011;4:683-93.
33. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, et al. Outcomes of patients with acute coronary syndrome and previous
coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the
Aggrastat to Zocor [A to Z] trials). Am J Cardiol 2008;102:552-8.
34. Christenson JT, Simonet F, Badel P, Schmuziger M. Evaluation of preoperative intra-aortic balloon pump support in high risk coronary
patients. Eur J Cardiothorac Surg 1997;11:1097-103; discussion 1104.
35. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, et al. Percutaneous coronary intervention versus coronary artery bypass graft
surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter,
randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious
Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol 2001;38:143-9.
36. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, et al. Coronary bypass graft fate and patient outcome: angiographic
follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26.
37. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, et al. Percutaneous coronary intervention versus coronary bypass graft
surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: the VA
AWESOME multicenter registry: comparison with the randomized clinical trial. J Am Coll Cardiol 2002;39:266-73.
38. Almomani A, Pothineni NV, Edupuganti M, Payne J, Agarwal S, et al. Outcomes of fractional flow reserve-based deferral in saphenous
vein graft narrowing. Am J Cardiol 2018;122:723-8.
39. Mehilli J. The VELETI II Trial (Sealing Moderate Coronary Saphenous Vein Graft Lesions With Paclitaxel-Eluting Stents): local
mechanical intervention fails to stop atheroprogression in saphenous vein grafts. Circ Cardiovasc Interv 2016;9.
40. Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions